Skip to content
Zerafil Dosing
Response Assessment
Response Assessment: Asthma
Response Assessment: Urticaria
Response Assessment: CRSwNP
Treatment Initiation
Treatment Initiation: Asthma
Treatment Initiation: Urticaria
Treatment Initiation: CRSwNP
Control Test
Control Test: Asthma (ACT)
Control Test: Urticaria (UCT)
Control Test: Sino-Nasal Outcome Test (SNOT-22)
Zerafil Dosing
Response Assessment
Response Assessment: Asthma
Response Assessment: Urticaria
Response Assessment: CRSwNP
Treatment Initiation
Treatment Initiation: Asthma
Treatment Initiation: Urticaria
Treatment Initiation: CRSwNP
Control Test
Control Test: Asthma (ACT)
Control Test: Urticaria (UCT)
Control Test: Sino-Nasal Outcome Test (SNOT-22)
Contact us
Response Assessment: Asthma
"
*
" indicates required fields
Step
1
of
2
0%
Has the patient received Zerafil® for 4 to 6 months?
*
*Note that the dosage of the patient's other medications should not have been changed during this period.
Yes
No
1. Reduction in annual exacerbations:
*
0 exacerbations or reduction ≥ 75%
Reduction of exacerbations 50 - 74%
Reduction of exacerbations < 50%
2. Reduction in daily OCS dose:
*
Stopping OCS or reduction ≥ 75%
Reduction of daily dose 50 - 74%
Reduction of daily dose < 50%
3. Improvement in Asthma Control Test (ACT) score:
*
Improvement ≥ 3 points and score ≥ 20 or improvement ≥ 6 points
Improvement by 3–5 points and score < 20
No clinically relevant improvement (<3 points)
Hidden
SUM
Overview of the Algorithms
